ArticleClinical nuclear medicine2026
Whole-body Dynamic [18F]FDG-PET/CT in Giant Cell Arteritis and Polymyalgia Rheumatica.
Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to explore the diagnostic efficacy of whole-body dynamic (WBD) acquisition using [18F]-Fluorodeoxyglucose-positron-emission-tomography/computed-tomography ([18F]FDG-PET/CT) for the assessment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) compared with the standard static PET/CT.
methodsTwenty-five patients with suspected GCA and/or PMR were prospectively enrolled in this single-center study. WBD PET imaging was performed before treatment using a standard PET/CT scanner with a multibed multipass dynamic whole-body acquisition approach (dPET). Reconstructed datasets were used to generate metabolic rate of [18F]FDG (MRFDG) images based on standard Patlak analysis. In case of pathologic FDG uptake, VOIs placed in vessel walls and joints were used for quantitation and definition of the target-to-background ratio (TBR): uptake in VOIs of vessel walls and joints (maximum values), to VOIs in blood pool (GCA), or to VOIs in normal muscles (PMR) (mean values). The final diagnosis based on the available imaging and laboratory results (except dPET), served as the standard of reference.
resultsSeventeen of the 25 patients (68%) showed pathologic FDG uptake, of which 5 (20%) were finally diagnosed with GCA alone, 6 (24%) with PMR alone, and another 6 (24%) with both conditions. TBR difference between dPET and static PET was significant in both diseases(GCA P<0.003, PMR P<0.003), and TBRs of dPET and static PET were significantly higher in both diseases compared with the healthy controls.
conclusionsWBD [18F]FDG-PET/CT provided a significantly higher TBR in patients with GCA and PMR compared with standard static PET imaging. WBD [18F]FDG-PET/CT may potentially enhance the diagnostic accuracy in detecting GCA and PMR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.